

# The Impact of Stress and Major Depressive Disorder on Hippocampal and Medial Prefrontal Cortex Morphology

Emily L. Belleau, Michael T. Treadway, and Diego A. Pizzagalli

## ABSTRACT

Volumetric reductions in the hippocampus and medial prefrontal cortex (mPFC) are among the most well-documented neural abnormalities in major depressive disorder (MDD). Hippocampal and mPFC structural reductions have been specifically tied to MDD illness progression markers, including greater number of major depressive episodes (MDEs), longer illness duration, and nonremission/treatment resistance. Chronic stress plays a critical role in the development of hippocampal and mPFC deficits, with some studies suggesting that these deficits occur irrespective of MDE occurrence. However, preclinical and human research also points to other stress-mediated neurotoxic processes, including enhanced inflammation and neurotransmitter disturbances, which may require the presence of an MDE and contribute to further brain structural decline as the illness advances. Specifically, hypothalamic-pituitary-adrenal axis dysfunction, enhanced inflammation and oxidative stress, and neurotransmitter abnormalities (e.g., serotonin, glutamate, gamma-aminobutyric acid) likely interact to facilitate illness progression in MDD. Congruent with stress sensitization models of MDD, with each consecutive MDE it may take lower levels of stress to trigger these neurotoxic pathways, leading to more pronounced brain volumetric reductions. Given that stress and MDD have overlapping and distinct influences on neurobiological pathways implicated in hippocampal and mPFC structural decline, further work is needed to clarify which precise mechanisms ultimately contribute to MDD development and maintenance.

**Keywords:** Depression, Hippocampus, Illness progression, Medial prefrontal cortex, Neuroprogression, Stress

<https://doi.org/10.1016/j.biopsych.2018.09.031>

Major depressive disorder (MDD) is frequently a chronic progressive illness. Approximately 60% of individuals with MDD will experience recurrent episodes, and each successive episode carries a 10% to 20% risk of failing to remit with current therapeutic approaches (1). While several neural pathways have been linked to the development and recurrence of depression, the hippocampus and medial prefrontal cortex (mPFC) have been repeatedly implicated in the pathophysiology and progression of this illness (2,3).


In this review, we examine clinical and preclinical data pointing to the pivotal role of stress in the development of hippocampal and mPFC abnormalities in depression and a chronic (often treatment-refractory) course of the disorder. Based on existing evidence, we propose a model (Figure 1) by which chronic/severe life stress can trigger the initial development of mPFC and hippocampal volume reductions. However, these reductions are neither necessary nor sufficient for inducing a major depressive episode (MDE). On the other hand, stress also instigates other neurotoxic processes (hypothalamic-pituitary-adrenal [HPA] axis dysregulation, inflammation, oxidative stress, and neurotransmitter disturbances) that interact and may drive the development of a chronic type of MDD marked by further reductions in hippocampal and

mPFC volumes. Expanding on recent conceptualizations, we highlight how each of these stress-linked neurotoxic processes has been related to hippocampal and mPFC structural aberrations and the development of persistent courses of depression.

## HIPPOCAMPUS AND mPFC VOLUME REDUCTIONS: CAUSE VERSUS CONSEQUENCE OF MDD?

MDD is phenomenologically, etiologically, and pathophysiologically highly heterogeneous. Consequently, identifying reliable biological or imaging markers has been significantly more challenging than anticipated. One exception has been structural imaging of the hippocampus and mPFC; several meta-analyses have demonstrated that relative to healthy control individuals (HCs), those with MDD show reduced hippocampus and mPFC volumes, including dorsal and ventral mPFC portions extending into the medial orbital frontal cortex as well as rostral and dorsal portions of the anterior cingulate cortex (2,4–14). These meta-analyses have reported moderate effect sizes for reduced hippocampal volume in MDD (Cohen's  $d$  range =  $-.41$  to  $-.47$ ) (6,8,9). While most studies have examined the whole hippocampus owing to spatial resolution

SEE COMMENTARY ON PAGE 436




**Figure 1.** The role of chronic stress and neurotoxic processes in brain volumetric reductions and major depressive disorder (MDD) illness progression. Chronic life stress can trigger the initial development of medial prefrontal cortex (mPFC) and hippocampal volume reductions. However, these reductions are neither necessary nor sufficient to produce a major depressive episode. On the other hand, stress also initiates a set of neurotoxic processes (hypothalamic-pituitary-adrenal [HPA] axis dysregulation, inflammation, and neurotransmitter disturbances) that interact and may drive the development of a more chronic type of MDD marked by further hippocampal and mPFC volume reductions.

limitations, those that have parcellated the hippocampus into different subfields have found evidence for reduced cornu ammonis 1 to 3, dentate gyrus/cornu ammonis 4, and subiculum volumes as well as both anterior and posterior subdivisions in MDD [e.g., (15,16)]. With respect to mPFC volume reductions, small to large effect sizes have been reported (Figure 2). Given that extant meta-analyses have also included portions of the PFC outside of the mPFC, we focused on calculating effect sizes for individual studies that targeted aspects of the mPFC, including the ventral mPFC/medial orbital frontal cortex, the rostral anterior cingulate cortex/dorsal anterior cingulate cortex, and the dorsal mPFC (Figure 2 and Supplemental Table S1). In addition, these estimates are likely

affected by antidepressant use and presence of other psychiatric comorbidities, given that they were not exclusionary in most studies. Notably, longitudinal studies have shown that common antidepressants lead to increases in hippocampus and mPFC volumes (17). Moreover, individuals with MDD and an anxiety disorder were found to have more pronounced mPFC reductions than those with just one disorder (18). Despite these effects, the volume reduction findings remain significant even when accounting for antidepressant use and common psychiatric comorbidities (5,7,8).

While the presence of hippocampal and mPFC volume reductions in first-onset MDD is mixed (2,7), they have been consistently associated with markers of a progressive course



**Figure 2.** Estimated effect sizes of hippocampal and medial prefrontal cortex (mPFC) volume reductions in major depressive disorder. The mPFC includes ventral portions of the mPFC (ventral mPFC [vmPFC] and medial orbitofrontal cortex) and dorsal portions of the mPFC (dorsal mPFC [dmPFC]) as well as rostral anterior cingulate cortex (rACC) and dorsal anterior cingulate cortex (dACC). In this figure, we provide a range and mean (SD) of effect sizes calculated from individual studies for each of the mPFC subdivisions. We also provide a range and mean (SD) of effect sizes for reduced hippocampal volumes in major depressive disorder calculated from three prior meta-analyses. Negative effect size values indicate that those with major depressive disorder have reduced mPFC and hippocampal volumes compared with healthy control individuals. Hipp, hippocampus.

of MDD characterized by more recurrent episodes/relapses (3,19–25), longer illness duration (24,26–30), and non-remission/treatment resistance (28,31–38). Importantly, a meta-analysis found that hippocampus volume reduction was found only in patients who had been depressed for at least 2 years and had more than one episode (2). More critically, longitudinal work has shown that hippocampal and mPFC volume reductions become more pronounced when depressive symptoms do not remit (35,38). These findings suggest that hippocampal and mPFC volume reductions may be a selective marker for the propensity toward and/or the consequence of episodic recurrence. However, contrary to this, several other studies have found that these structural changes may reflect a preexisting vulnerability to an MDE, particularly for individuals with certain genetic profiles and/or early life stress (ELS) histories (39–45).

Interestingly, a preclinical longitudinal study involving a chronic mild stress model of depression attempted to directly address the cause/consequence debate (46). This study found that both resilient rats and susceptible rats exhibiting a depressive phenotype were characterized by reduced hippocampal cell proliferation. In addition, among the susceptible rats, the development of depressive behaviors occurred prior to reductions in hippocampal cell proliferation (46). These results contradict both cause and consequence hypotheses of hippocampal abnormalities in MDD. Instead, this study suggests that hippocampal changes result from stress and are likely independent of MDE development. Consistent with this hypothesis, other preclinical work has demonstrated similar stress-related microstructural changes in the hippocampus in both resilient mice and mice exhibiting depressive behavior (47). In addition, longitudinal human imaging work has highlighted that greater baseline life stress was associated with the development of smaller hippocampal volumes 3 months later in a sample of HCs (48). A possible explanation for these seemingly contradictory findings may be that chronic stress drives initial hippocampal and mPFC abnormalities, but other risk factors need to be present (e.g., genetic, abnormal physiological response to stress) for development of an MDE. Moreover, possibly via the upregulation of stress-induced neurotoxic processes (e.g., inflammation, oxidative stress), further hippocampal decline occurs among individuals who develop chronic MDD. While the presence of hippocampal and mPFC damage alone might not be sufficient for inducing an MDE, recent work has shown that the induction of long-term potentiation within the hippocampus is sufficient to generate antidepressant effects (49). Thus, abnormalities within these structures may nevertheless contribute to the maintenance or exacerbation of depressive symptoms (see Table 1 for a cause vs. consequence debate synopsis).

## STRESS AND HIPPOCAMPAL/mPFC VOLUME REDUCTION IN MDD

Two classes of stress-related models, the stress sensitization and stress autonomy models, have been proposed to explain how relationships between stress and depression change as a function of illness course (50). Both models posit that while first MDEs are highly likely to follow periods of severe stress, the strength of this relationship declines as a function of illness

course. However, while the stress sensitization model hypothesizes that with recurrent episodes of depression more minor stressors are capable of triggering MDEs, the stress autonomy model posits that successive MDEs develop independent of stressful life events. In support of both models, prospective studies have found that the likelihood of a severe stressful life event occurring during the 3 months prior to an MDE onset was reduced among those with a prior history of depression compared with those experiencing their first MDE (51,52). However, more consistent with the stress sensitization model, these longitudinal studies also found that the likelihood of an MDE onset increased when nonsevere life stressors were present during the 3 months prior to the episode among those with a prior history of depression (51,52).

In addition, cross-sectional research examining the role of stressful life events in hippocampal and mPFC anomalies in MDD is supportive of both stress models. A human study found that a greater number of stressful life events during the 3 months prior to an initial MDE was linked to increased hippocampal volume reductions in male individuals with a first MDE (53). However, a recent study demonstrated that individuals with a history of multiple MDEs exhibited smaller hippocampal and mPFC volumes, yet reported less perceived life stress, than those with fewer episodes (3). This suggests that while high levels of stress may have an important role in initiating hippocampal vulnerabilities among individuals with a first MDE, this relationship may be weaker among those with recurrent MDEs. However, given the cross-sectional nature of this study, it is unclear whether the hippocampal declines were driven by lower stress levels (supportive of a stress sensitization model) or were occurring independent of stress (supportive of a stress autonomy model). Future prospective work is needed to clarify whether hippocampal and mPFC volume decline related to MDD illness progression is linked to stress-dependent or -independent mechanisms.

While stress-related models of MDD have historically focused on relationships between recent life stressors and MDE onset, researchers have expanded these models to incorporate ELS. Consistent with the stress sensitization model, longitudinal research examining relationships among ELS, recent life stressors, and development of MDEs has shown that individuals with an ELS history are more prone to developing an MDE under less amounts of recent life stress than those without an ELS history (54,55). Further bolstering connections between ELS and illness progression, a meta-analysis found that a history of childhood maltreatment was associated with a greater probability of developing recurrent and persistent cycles of depression as well as treatment resistance (56). Imaging studies have also demonstrated that an ELS history was associated with hippocampal and mPFC volumetric decline (57–65). Some of these studies have noted that the relationship may be independent of the presence of MDD (61,64,65). However, the link between ELS and the development of chronic courses of depression marked by greater hippocampal and mPFC damage may be mediated by the persistent manifestation of neurotoxic processes that are triggered by even minor stressors. Congruent with this idea, one study found that individuals with an ELS history, both with and without an MDD diagnosis, exhibited increased adrenocorticotrophic hormone levels in response to a moderate

**Table 1. A Summary of the Cause Versus Consequence Debate of Hippocampal and mPFC Volume Reductions in MDD**

| Cause: mPFC and Hippocampal Volume Reductions Cause Initial MDD Onset                                                         | Consequence: mPFC and Hippocampal Volume Reductions Occur as a Result of Having Multiple MDEs                             | Independence: mPFC and Hippocampal Volume Reductions Are a Result of Stress and Independent of MDD Development                      |
|-------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------|
| Longitudinal human studies show that mPFC and hippocampal volume reductions occur prior to MDD onset (40,44,45)               | mPFC and hippocampal volume reductions correlate with MDD illness progression markers (3,19–38)                           | Chronic stress animal models show that hippocampal abnormalities occur in both stress-resilient and MDD-susceptible animals (46,47) |
| Human studies show that hippocampal and mPFC volume reductions in unaffected samples are at increased risk for MDD (39,41–43) | Longitudinal studies show that mPFC and hippocampal volume reductions are more pronounced when MDD does not remit (35,38) | Studies have linked chronic life stress with hippocampal volume reductions in healthy individuals (48)                              |

A body of human research has supported the hypothesis that hippocampal and mPFC volume reductions occur prior to the onset of depression and ultimately cause a first MDE. However, independent evidence has shown that hippocampal and mPFC deficits are found only among those with a history of major depressive episodes and greater illness progression. Furthermore, a third hypothesis has emerged from preclinical and human research, demonstrating that hippocampal and mPFC deficits are produced by stress and occur irrespective of whether depressive symptomatology emerges.

MDD, major depressive disorder; MDE, major depressive episode; mPFC, medial prefrontal cortex.

laboratory stressor compared with HCs and individuals with MDD without ELS. Individuals with both an MDD diagnosis and an ELS history showed the highest stress-related adrenocorticotrophic hormone response (66). Fitting stress sensitization models of MDD, there is also evidence that ELS enhances inflammatory responses to minor daily life stressors during adulthood (67). However, further longitudinal work linking ELS, recent life stress, neural deficits, and the development of recurrent depressive cycles is warranted to further clarify these relationships.

### THE ROLE OF HPA AXIS DYSREGULATION IN STRESS-MEDIATED HIPPOCAMPAL AND mPFC DEFICITS

Animal models have established that prolonged stress can lead to HPA axis hyperreactivity and depressive behaviors along with hippocampal and mPFC abnormalities (68,69). Specifically, excessively high, as well as blunted, glucocorticoid receptor expression has been linked to reduced neurogenesis within the dentate gyrus (69). Higher circulating levels of glucocorticoids have also been shown to cause neuronal atrophy and dendritic retraction within the mPFC (70).

In accordance with the animal literature, a meta-analysis of clinical studies noted that individuals with MDD showed higher basal cortisol levels, particularly in the afternoon when cortisol levels should be dropping (71). However, this meta-analysis highlighted substantial variability in HPA axis functioning in MDD (71). Longitudinal studies have found that both enhanced and blunted cortisol levels predicted MDE recurrence among those with a prior history of MDD (72–74). Similarly, cortisol responses to a laboratory psychosocial stressor in MDD are mixed, with some showing cortisol hyperreactivity and others showing hyporeactivity (75,76).

One of the factors complicating the interpretation of abnormal cortisol levels in MDD is the potential presence of glucocorticoid resistance (77). A lower cortisol output may reflect its bioavailability, or it may be an indicator of reduced responsiveness to the presence of glucocorticoids (77). In addition, even in the presence of cortisol hypersecretion, elevated cortisol may represent an attempt to counteract inflammatory responses in the presence of high glucocorticoid

levels (77). Thus, a measure of glucocorticoid expression is also needed to clarify the pathophysiology of HPA axis aberrations leading to MDD-related neural abnormalities. Another confounding factor is antidepressant use, which has been found to reduce HPA axis activity (78). Thus, further research is needed to tease apart which mechanisms may contribute to different aspects of HPA dysregulation in depression.

Relatedly, HPA axis dysregulation has also been associated with hippocampal and mPFC structural abnormalities. Specifically, higher baseline cortisol levels, as well as higher cortisol/dehydroepiandrosterone ratios, have been linked to smaller hippocampal and mPFC volumes among HC and MDD samples (79,80), further highlighting the importance of stress (rather than the presence of MDD per se) in facilitating initial structural damage. Critically, animal models have shown that dehydroepiandrosterone reduces the adverse effects of cortisol on the central nervous system (81), so it is likely important to consider other stress-related hormones when assessing cortisol levels.

However, in addition to these positive findings, several imaging studies in MDD have failed to find associations between cortisol and structural abnormalities (82–87). This may partly reflect evidence supporting the impact of chronic stress and persistent types of MDD on mPFC and hippocampal morphology. Importantly, these studies did not report on levels of life stress prior to neuroimaging assessment. Moreover, none of these studies examined whether relationships between structural deficits and cortisol levels vary as a function of clinical MDD illness progression markers (e.g., number of MDEs, illness duration) of MDD. In addition, given that these studies are cross-sectional, and brain structural changes may occur long after stress exposure, prospective studies are needed to link distinct cortisol trajectories with different life stress profiles, structural deficits, and illness course. This would clarify potential HPA axis-related mechanisms leading to hippocampal and mPFC decline in MDD.

### STRESS-MEDIATED INFLAMMATORY PATHWAYS TO HIPPOCAMPAL AND mPFC DEFICITS IN MDD

Another possible stress-related mechanism linking structural changes in the hippocampus and mPFC to MDD illness

progression is inflammation (88). Particularly relevant to this review, animal models have demonstrated that chronic unpredictable stress promotes the production of proinflammatory cytokines in the hippocampus (89) and mPFC (90,91). Moreover, the stimulating effects of peripheral proinflammatory cytokines on brain microglia can result in reduced hippocampal neurogenesis (92). Thus, stress-mediated enhancement of central and peripheral proinflammatory cytokines may contribute to subsequent structural alterations. With respect to connections with MDD, a preclinical chronic stress study demonstrated that mice exhibiting anhedonic behavior (but not stress-resilient mice) showed enhanced inflammation in the mPFC (90). This suggests that some stress-related mPFC and hippocampal inflammatory processes may require the presence of depressive symptomatology in addition to stress.

Accordingly, recent imaging studies in individuals with depression have reported enhanced neuroinflammation in the hippocampus and mPFC compared with HCs (93,94). In addition, higher levels of peripheral proinflammatory cytokines, greater expression of inflammation-related genes, and reduced expression of neuroprotective genes all have been associated with greater hippocampal volume decline and mPFC thinning in MDD (95–97). Enhanced peripheral inflammation has also been related to MDD recurrence/relapse, number of episodes, illness duration, and treatment nonresponse (98–100). However, responders to antidepressant treatment showed reduced peripheral inflammation over the course of treatment compared with nonresponders (101).

### **OXIDATIVE STRESS AS A MECHANISM CONTRIBUTING TO MDD-RELATED BRAIN STRUCTURAL DEFICITS**

Closely tied to inflammatory mechanisms, preclinical studies have also demonstrated that chronic stress initiates production of oxidative stress and impairment of antioxidant defense mechanisms in the hippocampus and mPFC (102). This can result in hippocampal and mPFC cellular damage and reduced hippocampal neurogenesis (102), likely contributing to hippocampal and mPFC atrophy. With respect to MDD, increased oxidative stress, lower antioxidant levels, and imbalanced oxidant:antioxidant levels have been well documented within the hippocampus (103,104) and mPFC (104–106), resulting in associated markers of DNA/RNA damage in these regions. While few studies have examined relationships between oxidative stress and brain structural deficits in MDD, one study found that lower antioxidant levels were associated with more pronounced hippocampal volume reductions in MDD (107). Consistent with neural markers of progressive illness, greater oxidative stress, lower antioxidant, and greater oxidative stress-related DNA/RNA damage have been linked to clinical markers of MDD illness progression, including greater chronicity, more MDEs, and treatment resistance (98,108–113). Conversely, response to antidepressant treatment has been shown to normalize the oxidant:antioxidant imbalance seen in MDD (108). Findings to date suggest a psychosocial stress-induced oxidative stress pathway that contributes to hippocampus and mPFC structural deficits in MDD.

### **SEROTONIN DYSFUNCTION CONTRIBUTES TO BRAIN STRUCTURAL DECLINE AND MDD ILLNESS PROGRESSION**

Neurotransmitter disturbances, such as serotonin dysfunction, are likely prominent pathways to illness progression in MDD. Preclinical chronic mild stress models of depression show reduced serotonin concentration, expression, release, and neurotransmission in both the hippocampus and mPFC (114–116). Interestingly, a study comparing stress-resilient mice with mice exhibiting anhedonic behavior noted that stress-elevated expression of serotonin 2A receptors within the mPFC occurred in both groups of mice, whereas additional serotonin transporter elevations occurred exclusively in the depression-susceptible mice (90). This suggests that some stress-related serotonergic abnormalities are independent of the development of depressive behavior, whereas others are specific to anhedonia development.

While the animal literature has demonstrated clear pathways to serotonin dysregulation within specific brain regions that are linked to depressive behaviors, human imaging findings in MDD have been more mixed (117–119). There has been evidence of decreased serotonin 1A receptor messenger RNA levels within the hippocampus of individuals with MDD compared with HCs (117). Conversely, two recent meta-analyses failed to find significant alterations in serotonin transporter binding/availability in the hippocampus and mPFC in MDD (118,119). Discrepancies may be due to clinical heterogeneity, including illness stage, particularly because greater serotonin dysfunction has been described among individuals with MDD who have experienced a greater number of past MDEs (120).

Few studies have examined associations between hippocampal/mPFC volume reductions and serotonin system dysfunction. Recent longitudinal studies have linked smaller hippocampal volumes to MDD onset among individuals with ELS and carrying the S allele of the serotonin transporter gene, which is associated with reduced serotonin uptake (44,45). One of these studies noted that greater parental display of positive behaviors was protective against hippocampal volume reductions among those carrying the S allele. However, these connections have yet to be explored in conjunction with MDD illness progression markers, which is an important area for future research given the connection between greater serotonin dysfunction and number of MDEs. In addition, more studies are needed to clarify which serotonergic disturbances are consequences of stress that do not necessarily lead to MDD and which ones result in MDD development.

### **GLUTAMATERGIC CONTRIBUTIONS TO MDD-RELATED BRAIN STRUCTURAL DECLINE**

The glutamate system is also highly affected by stress. Chronic stress disrupts glutamate release, glutamate clearance from the synapse, and glutamate transmitter expression, but the direction of the effects is region specific (121). Some studies have reported enhanced chronic stress-related glutamate release and glutamate receptor expression but reduced glutamate clearance/metabolism in the hippocampus (122,123). A study that directly compared stress-resilient mice with stress-susceptible mice displaying depressive behaviors indicated that enhanced

hippocampal glutamate expression was unique to depression-susceptible mice (122). A different pattern has been described in the mPFC, with some reporting reduced chronic stress-related glutamate receptor expression, which has been speculated as a potential protective mechanism against excessive glutamate signaling and excitotoxicity [e.g., (124,125)]. However, these studies did not examine potential differences between stress-resilient and MDD-susceptible mice. In contrast to these results, reduced glutamate clearance (and thus enhanced accumulation of glutamate in the mPFC) has been shown to produce anhedonic behaviors (126). Accordingly, increased chronic stress-related glutamate expression in the hippocampus and mPFC may be unique to those who develop the depressive phenotype.

With respect to *in vivo* human imaging work in MDD, magnetic resonance spectroscopy studies have provided evidence of glutamate dysfunction in MDD [e.g., (127,128)]. However, the glutamate measures are primarily intracellular, so it is difficult to interpret relationships with glutamate neurotransmission. In addition, many of these studies have reported on combined glutamate and glutamine metabolite levels or metabolite ratios, further complicating interpretations. In general, studies have found reduced glutamate as well as combined glutamate and glutamine levels in the mPFC and hippocampus in MDD, with individuals who have a more chronic course showing greater declines compared with individuals who are experiencing a first episode (127,128). Reduced glutamate levels may reflect cellular abnormalities associated with decreased glutamate availability resulting from hyperactive glutamate neurotransmission (129). While it has yet to be applied to MDD samples, a human imaging study noted associations between increased extracellular glutamate levels and hippocampal volume reductions (130).


There is also emerging evidence of impaired glutamate-glutamine cycling in the mPFC and hippocampus among those with MDD. Glutamate is produced in neurons from

glutamine by glutamase. Astrocytes uptake glutamate once it is released from the synaptic terminal and convert glutamate back to glutamine via glutamine synthase. A preclinical study showed that inhibiting glutamine synthase and glutamine transport in the mPFC led to the development of depressive behavior (131). In addition, another preclinical study showed that enhanced stimulation of glutamate cycling in the mPFC via three different classes of antidepressants was associated with the onset of rapid antidepressant action (132). Several human postmortem studies have also shown reductions in the expression of several components critical to astrocyte function, largely in the mPFC, but also some evidence in the hippocampus, suggesting impaired glutamate-glutamine cycling (133). Together, these findings indicate that glutamate dysregulation likely has a strong role in neural and clinical markers of MDD illness progression.

### GAMMA-AMINOBUTYRIC ACIDERGIC DISTURBANCES ASSOCIATED WITH BRAIN STRUCTURAL DECLINE AND CHRONIC MDD

Gamma-aminobutyric acid (GABA) is also likely centrally involved in hippocampal and mPFC abnormalities in MDD (134). With respect to preclinical models of depression, chronic stress has been shown to decrease GABA expression in the hippocampus and mPFC (135,136). Serotonin is known to regulate the GABAergic system (137). Therefore, when the serotonin system is dysregulated, this can contribute to reduced GABAergic inhibitory control, resulting in enhanced glutamate and HPA axis reactivity and ultimately reduced hippocampal neurogenesis (124,138).

Several human magnetic resonance spectroscopy studies have reported lower mPFC GABA levels in MDD (139–141). Reduced mPFC GABA levels in MDD have been associated with smaller hippocampal volumes (139) and treatment resistance



**Figure 3.** A stress-mediated neurotoxic pathway leading to chronic major depressive disorder (MDD) hippocampal and medial prefrontal cortex volume reduction. Chronic stress sets off a cascade of neurotoxic processes. The presence of chronic stress triggers dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, which can be either enhanced or blunted due to glucocorticoid resistance. This HPA axis dysregulation triggers the immune system, leading to enhanced inflammation (stress can also have a direct effect on inflammation not mediated by the HPA axis). In turn, enhanced inflammation can produce further dysregulation of the HPA axis. Proinflammatory cytokines then activate indoleamine 2,3-dioxygenase (IDO), an enzyme that catabolizes tryptophan, leading to serotonin depletion and the production of kynurenine. Kynurenine can be converted to neurotoxic 3-hydroxykynurenine (3HK) and quinolinic acid, which can increase glutamate release and oxidative stress as well as reduce gamma-aminobutyric acid (GABA) inhibitory control. Dysregulated serotonin levels lead to further reductions in GABA inhibitory control. This reduction in GABA inhibitory control

can lead to further glutamate release. With successive major depressive episodes, even minor levels of stress can trigger this pathway, leading to further hippocampal and medial prefrontal cortex volume decline. Genetic risk profiles can also increase vulnerability to chronic stress triggering of these neurotoxic pathways to illness progression and brain structural decline.

(142,143). However, antidepressants known to target the monoaminergic system have also been shown to counteract GABAergic abnormalities (134). This suggests that GABA may have a key role in multiple pathways leading to hippocampal and mPFC structural deficits in MDD and treatment resistance.

### A COMMON PATHWAY LEADING TO MDD ILLNESS PROGRESSION-RELATED HIPPOCAMPAL AND mPFC VOLUME REDUCTIONS

Based on the above evidence, it is likely that these neurotoxic processes interact to form multiple pathways leading to hippocampal and mPFC volume decline and MDD illness progression. One possible common pathway involves chronic stress triggering HPA axis dysfunction and enhanced production of cell-mediated immune cytokines, which activate indoleamine 2,3-dioxygenase (68), an enzyme that catabolizes tryptophan, leading to serotonin depletion and production of kynurenine. Kynurenine is then converted to neuroprotective metabolites (kynurenic acid) or neurotoxic metabolites (3-hydroxykynurenine and quinolinic acid) (68). The production of neurotoxic 3-hydroxykynurenine and quinolinic acid leads to increased glutamate and oxidative stress as well as reduced GABAergic inhibitory control. Given the connection between serotonin and GABA, reduced serotonin also contributes to decreased GABA expression. Together, this pathway may trigger hippocampal and mPFC cellular damage and volume reductions (138,144,145). In line with stress sensitization models, with each successive MDE, it may take smaller amounts of stress to trigger these pathways and produce further brain structural decline. ELS and genetic risk profiles may program this vulnerability early on by enhancing psychological and biological reactivity to minor stressful life events (Figure 3). In support of this pathway, a study found that a lower kynurenic acid/quinolinic acid ratio correlated with reduced hippocampal volumes (146). Moreover, both reduced kynurenic acid/quinolinic acid and kynurenic acid/3-hydroxykynurenine ratios partially mediated the relationship between MDD and mPFC cortical thinning (147). In addition, preclinical evidence suggests that neurotoxic dorsal hippocampal kynurenine metabolism may drive depressive behavior when inflammation is enhanced (148).

### CONCLUSIONS

The proposed model provides numerous directions for future research. Much of the preclinical literature has focused on the impact of chronic stress on the hippocampus and mPFC without directly comparing animals that did not exhibit depressive behaviors (resilient phenotype) versus those that exhibited depressive behaviors (susceptible phenotype). Those studies that directly compared the two groups have provided some promising leads on identifying which neurotoxic processes affecting hippocampal and mPFC structure are unique to the development of depression. This work can inform which neurotoxic components to target in future prospective studies of MDD and brain structural decline. Prospective studies focusing on at-risk samples by virtue of living in highly stressful environments would address which stress-related neurotoxic processes affecting hippocampal and mPFC structure are relevant to MDD onset and which processes are implicated at different stages of MDD illness. In addition, these studies would clarify temporal relationships

among neurotoxic processes, hippocampal and mPFC structural aberrations, and MDD illness progression. This would allow for a more precise identification of stress-related mechanisms signifying biomarkers of MDD, which could lead to more effective treatment targets.

### ACKNOWLEDGMENTS AND DISCLOSURES

This work was supported by a Kaplen Fellowship (Harvard Medical School), an Adam J. Corneel Young Investigator Award (McLean Hospital), and a Klingenstein Third Generation Foundation Postdoctoral Fellowship (all to ELB); by National Institute of Mental Health (NIH) Grant Nos. R00 MH102355 and R01 MH108605 (to MTT); and by NIH Grant Nos. R37 MH068376, R01 MH101521, 1R01 MH108602, and R01 MH095809 (to DAP). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

During the past 3 years, MTT has served as a paid consultant to NeuroCog Trials, Avanir Pharmaceuticals, and BlackThorn Therapeutics. Over the past 3 years, DAP has received consulting fees from Akili Interactive Labs, BlackThorn Therapeutics, Boehringer Ingelheim, Posit Science, and Takeda Pharmaceuticals for activities unrelated to the current review. No funding from these entities was used to support the current work, and all views expressed are solely those of the authors. ELB reports no biomedical financial interests or potential conflicts of interest.

### ARTICLE INFORMATION

From McLean Hospital (ELB, DAP), Belmont, and Harvard Medical School (ELB, DAP), Boston, Massachusetts; and Department of Psychology (MTT), Emory University, Atlanta, Georgia.

Address correspondence to Diego A. Pizzagalli, Ph.D., Center for Depression, Anxiety and Stress Research, McLean Hospital, 115 Mill Street, de Marnette Building, Room 233C, Belmont, MA 02478; E-mail: [dap@mclean.harvard.edu](mailto:dap@mclean.harvard.edu).

Received Apr 6, 2018; revised Jul 25, 2018; accepted Sep 10, 2018.

Supplementary material cited in this article is available online at <https://doi.org/10.1016/j.biopsych.2018.09.031>.

### REFERENCES

1. Monroe SM, Harkness K (2011): Recurrence in major depression: A conceptual analysis. *Psychol Rev* 118:655–674.
2. McKinnon MC, Yucel K, Nazarov A, MacQueen GM (2009): A meta-analysis examining clinical predictors of hippocampal volume in patients with major depressive disorder. *J Psychiatry Neurosci* 34:41–54.
3. Treadway MT, Waskom ML, Dillon DG, Holmes AJ, Park MTM, Chakravarty MM, et al. (2015): Illness progression, recent stress, and morphology of hippocampal subfields and medial prefrontal cortex in major depression. *Biol Psychiatry* 77:285–294.
4. Videbech P, Ravnkilde B (2004): Hippocampal volume and depression: A meta-analysis of MRI studies. *Am J Psychiatry* 161:1957–1966.
5. Campbell S, Marriott M, Nahmias C, MacQueen GM (2004): Lower hippocampal volume in patients suffering from depression: A meta-analysis. *Am J Psychiatry* 161:598–607.
6. Koolschijn PCMP, van Haren NEM, Lensvelt-Mulders GJLM, Hulshoff Pol HE, Kahn RS (2009): Brain volume abnormalities in major depressive disorder: A meta-analysis of magnetic resonance imaging studies. *Hum Brain Mapp* 30:3719–3735.
7. Cole J, Costafreda SG, McGuffin P, Fu CHY (2011): Hippocampal atrophy in first episode depression: A meta-analysis of magnetic resonance imaging studies. *J Affect Disord* 134:483–487.
8. Kempton MJ (2011): Structural neuroimaging studies in major depressive disorder. *Arch Gen Psychiatry* 68:675–690.
9. Arnone D, McIntosh AM, Ebmeier KP, Munafò MR, Anderson IM (2012): Magnetic resonance imaging studies in unipolar depression: Systematic review and meta-regression analyses. *Eur Neuropsychopharmacol* 22:1–16.

10. Bora E, Fornito A, Pantelis C, Yücel M (2012): Gray matter abnormalities in major depressive disorder: A meta-analysis of voxel based morphometry studies. *J Affect Disord* 138:9–18.
11. Du MY, Wu QZ, Yue Q, Li J, Liao Y, Kuang WH, *et al.* (2012): Voxelwise meta-analysis of gray matter reduction in major depressive disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 36:11–16.
12. Lai CH (2013): Gray matter volume in major depressive disorder: A meta-analysis of voxel-based morphometry studies. *Psychiatry Res Neuroimaging* 211:37–46.
13. Amone D, Job D, Selvaraj S, Abe O, Amico F, Cheng Y, *et al.* (2016): Computational meta-analysis of statistical parametric maps in major depression. *Hum Brain Mapp* 37:1393–1404.
14. Wise T, Radua J, Via E, Cardoner N, Abe O, Adams TM, *et al.* (2017): Common and distinct patterns of grey-matter volume alteration on major depression and bipolar disorder: Evidence from voxel-based meta-analysis. *Mol Psychiatry* 22:1455–1463.
15. Han K-M, Won E, Sim Y, Tae W-S (2016): Hippocampal subfield analysis in medication-naïve female patients with major depressive disorder. *J Affect Disord* 194:21–29.
16. Malykhin NV, Carter R, Seres P, Coupland NJ (2010): Structural changes in the hippocampus in major depressive disorder: Contributions of disease and treatment. *J Psychiatry Neurosci* 35:337–343.
17. Frodl T, Jager M, Smajstrlova I, Born C, Bottlender R, Palladino T, *et al.* (2008): Effect of hippocampal and amygdala volumes on clinical outcomes in major depression: A 3-year prospective magnetic resonance imaging study. *J Psychiatry Neurosci* 33:423–430.
18. van Tol M-J, van der Wee NJA, van den Heuvel OA, Nielen MMA, Demenescu LR, Aleman A, *et al.* (2010): Regional brain volume in depression and anxiety disorders. *Arch Gen Psychiatry* 67:1002–1011.
19. MacQueen GM, Campbell S, McEwen BS, Macdonald K, Amano S, Joffe RT, *et al.* (2003): Course of illness, hippocampal function, and hippocampal volume in major depression. *Proc Natl Acad Sci U S A* 100:1387–1392.
20. Kronmüller KT, Pantel J, Köhler S, Victor D, Giesel F, Magnotta VA, *et al.* (2008): Hippocampal volume and 2-year outcome in depression. *Br J Psychiatry* 192:472–473.
21. Yucel K, McKinnon MC, Chahal R, Taylor VH, MacDonald K, Joffe R, *et al.* (2008): Anterior cingulate volumes in never-treated patients with major depressive disorder. *Neuropsychopharmacology* 33:3157–3163.
22. Stratmann M, Konrad C, Kugel H, Krug A, Schoning S, Ohrmann P, *et al.* (2014): Insular and hippocampal gray matter volume reductions in patients with major depressive disorder. *PLoS One* 9:e102692.
23. Wisse LEM, Biessels GJ, Stegenga BT, Kooistra M, van der Veen PH, Zwanenburg JJM, *et al.* (2015): Major depressive episodes over the course of 7 years and hippocampal subfield volumes at 7 Tesla MRI: The PREDICT-MR study. *J Affect Disord* 175:1–7.
24. Bludau S, Bzdok D, Gruber O, Kohn N, Riedl V, Sorg C, *et al.* (2016): Medial prefrontal aberrations in major depressive disorder revealed by cytoarchitecturally informed voxel-based morphometry. *Am J Psychiatry* 173:291–298.
25. Mathias SR, Knowles EEM, Kent JW, McKay DR, Curran JE, de Almeida MAA, *et al.* (2016): Recurrent major depression and right hippocampal volume: A bivariate linkage and association study. *Hum Brain Mapp* 37:191–202.
26. Sheline YI, Wang PW, Gado MH, Csernansky JG, Vannier MW (1996): Hippocampal atrophy in recurrent major depression. *Proc Natl Acad Sci U S A* 93:3908–3913.
27. Sheline YI, Sanghavi M, Mintun MA, Gado MH (1999): Depression duration but not age predicts hippocampal volume loss in medically healthy women with recurrent major depression. *J Neurosci* 19:5034–5043.
28. Sheline YI, Gado MH, Kraemer HC (2003): Untreated depression and hippocampal volume loss. *Am J Psychiatry* 160:1516–1518.
29. Serra-Blasco M, Portella MJ, Gómez-Ansón B, de Diego-Adelino X, Vives-Gilabert Y, Puigdemont D, *et al.* (2013): Effects of illness duration and treatment resistance on grey matter abnormalities in major depression. *Br J Psychiatry* 202:434–440.
30. Travis S, Coupland NJ, Silversone PH, Huang Y, Fujiwara E, Carter R, *et al.* (2015): Dentate gyrus volume and memory performance in major depressive disorder. *J Affect Disord* 172:159–164.
31. Hsieh MH, McQuoid DR, Levy RM, Payne ME, MacFall JR, Steffens DC (2002): Hippocampal volume and antidepressant response in geriatric depression. *Int J Geriatr Psychiatry* 17:519–525.
32. Frodl T, Meisenzahl EM, Zetzsche T, Hohne T, Banac S, Schorr C, *et al.* (2004): Hippocampal and amygdala changes in patients with major depressive disorder and healthy controls during a 1-year follow-up. *J Clin Psychiatry* 65:492–499.
33. MacQueen GM, Yucel K, Taylor VH, Macdonald K, Joffe R (2008): Posterior hippocampal volumes are associated with remission rates in patients with major depressive disorder. *Biol Psychiatry* 64:880–883.
34. Hoogenboom W, Perlis R (2012): Feasibility of studying brain morphology in major depressive disorder with structural magnetic resonance imaging and clinical data from the electronic medical record. *Psychiatry Res* 211:202–213.
35. Taylor WD, McQuoid DR, Payne ME, Zannas AS, MacFall JR, Steffens DC (2014): Hippocampus atrophy and the longitudinal course of late-life depression. *Am J Geriatr Psychiatry* 22:1504–1512.
36. Phillips JL, Batten LA, Tremblay P, Aldosary F, Blier P (2015): A prospective, longitudinal study of the effect of remission on cortical thickness and hippocampal volume in patients with treatment-resistant depression. *Int J Neuropsychopharmacol* 18:1–9.
37. Serra-Blasco M, de Diego-Adelino J, Vives-Gilabert Y, Trujols J, Puigdemont D, Carceller-Sindreu M, *et al.* (2016): Naturalistic course of major depressive disorder predicted by clinical and structural neuroimaging data: A 5-year follow-up. *Depress Anxiety* 33:1055–1064.
38. Frodl TS, Koutsouleris N, Bottlender R, Born C, Jager M, Scupin I, *et al.* (2008): Depression-related variation in brain morphology over 3 years. *Arch Gen Psychiatry* 65:1156–1165.
39. Chen MC, Hamilton JP, Gotlib IH (2010): Decreased hippocampal volume in healthy girls at risk of depression. *Arch Gen Psychiatry* 67:270–276.
40. Rao U, Chen L, Bidesi AS, Shad MU, Thomas MA, Hammen CL (2011): Hippocampal changes associated with early-life adversity and vulnerability to depression. *Biol Psychiatry* 67:357–364.
41. Amico F, Meisenzahl E, Koutsouleris N, Reiser M, Moller HJ, Frodl T (2011): Structural MRI correlates for vulnerability and resilience to major depressive disorder. *J Psychiatry Neurosci* 36:15–22.
42. Carballo A, Lisiecka D, Fagan A, Saleh K, Ferguson Y, Connolly G, *et al.* (2012): Early life adversity is associated with brain changes in subjects at family risk for depression. *World J Biol Psychiatry* 13:569–578.
43. Holmes AJ, Lee PH, Hollinshead MO, Bakst L, Roffman JL, Smoller JW, *et al.* (2012): Individual differences in amygdala-medial prefrontal anatomy link negative affect, impaired social functioning, and polygenic depression risk. *J Neurosci* 32:18087–18100.
44. Little K, Olsson CA, Whittle S, Youssef GJ, Byrne ML, Simmons JG, *et al.* (2014): Association between serotonin transporter genotype, brain structure and adolescent-onset major depressive disorder: A longitudinal prospective study. *Transl Psychiatry* 4:e445.
45. Little K, Olsson CA, Youssef GJ, Whittle S, Simmons JG, Yucel M, *et al.* (2015): Linking the serotonin transporter gene, family environments, hippocampal volume and depression onset: A prospective imaging gene × environment analysis. *J Abnorm Psychol* 124:834–849.
46. Jayatissa MN, Henningsen K, Nikolajsen G, West MJ, Wiborg O (2010): A reduced number of hippocampal granule cells does not associate with an anhedonia-like phenotype in a rat chronic mild stress model of depression. *Stress* 13:95–105.
47. Delgado y Palacios R, Campo A, Henningsen K, Verhoye M, Poot D, Dijkstra J, *et al.* (2011): Magnetic resonance imaging and spectroscopy reveal differential hippocampal changes in anhedonic and resilient subtypes of the chronic mild stress rat model. *Biol Psychiatry* 70:449–457.
48. Papagni SA, Benetti S, Arulanantham S, Mccrory E, McGuire P, Mechelli A (2011): Effects of stressful life events on human brain

- structure: A longitudinal voxel-based morphometry study. *Stress* 14:227–232.
49. Kanzari A, Bourrier-Lucas C, Freysson A, Abrous DN, Haddjeri N, Lucas G (2018): Inducing a long-term potentiation in the dentate gyrus is sufficient to produce rapid antidepressant effects. *Mol Psychiatry* 23:587–596.
50. Monroe SM, Harkness KL (2005): Life stress, the “kindling” hypothesis, and the recurrence of depression: Considerations from a life stress perspective. *Psychol Rev* 112:417–445.
51. Ormel J, Oldehinkel AJ, Brilman EI (2001): The interplay of neuroticism, difficulties, and life events in the etiology of major and sub-syndromal, first and recurrent depressive episodes in later life. *Am J Psychiatry* 158:885–891.
52. Stroud CB, Davila J, Hammen C, Vrshek-Schallhorn S (2011): Severe and nonsevere events in first onsets versus recurrences of depression: Evidence for stress sensitization. *J Abnorm Psychol* 120:142–154.
53. Kronmüller KT, Pantel J, Götz B, Kohler S, Victor D, Mudt C, *et al.* (2008): Life events and hippocampal volume in first-episode major depression. *J Affect Disord* 110:241–247.
54. Hammen C, Henry R, Daley SE (2000): Depression and sensitization to stressors among young women as a function of childhood adversity. *J Consult Clin Psychol* 68:782–787.
55. Oldehinkel AJ, Ormel J, Verhulst FC, Nederhof E (2014): Childhood adversities and adolescent depression: A matter of both risk and resilience. *Dev Psychopathol* 26:1067–1075.
56. Nanni V, Uher R, Danese A (2012): Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: A meta-analysis. *Am J Psychiatry* 169:141–151.
57. Vythilingam M, Heim C, Newport J, Miller AH, Anderson E, Bronen R, *et al.* (2002): Childhood trauma associated with smaller hippocampal volume in women with major depression. *Am J Psychiatry* 159:2072–2080.
58. Treadway MT, Grant MM, Ding Z, Hollon SD, Gore JC, Shelton RC (2009): Early adverse events, HPA activity and rostral anterior cingulate volume in MDD. *PLoS One* 4:e4887.
59. Frodl T, Reinhold E, Koutsouleris N, Donohoe G, Bondy B, Reiser M, *et al.* (2010): Childhood stress, serotonin transporter gene and brain structures in major depression. *Neuropsychopharmacology* 35:1383–1390.
60. Frodl T, Reinhold E, Koutsouleris N, Reiser M, Meisenzahl EM (2010): Interaction of childhood stress with hippocampus and prefrontal cortex volume reduction in major depression. *J Psychiatr Res* 44:799–807.
61. Opel N, Redlich R, Zwanzger P, Grotegerd D, Arolt V, Heindel W, *et al.* (2014): Hippocampal atrophy in major depression: A function of childhood maltreatment rather than diagnosis. *Neuropsychopharmacology* 39:2723–2731.
62. Gerritsen L, Van Velzen L, Schmaal L, van der Graaf Y, van der Wee N, van Tol M-J, *et al.* (2015): Childhood maltreatment modifies the relationship of depression with hippocampal volume. *Psychol Med* 45:3517–3526.
63. Colle R, Segawa T, Chupin M, Tran Dong, MNT, Hardy P, Falissard B, *et al.* (2017): Early life adversity is associated with a smaller hippocampus in male but not female depressed in-patients: A case-control study. *BMC Psychiatry* 17:71.
64. Chaney A, Carballo A, Amico F, Fagan A, Skokauskas N, Meaney J, *et al.* (2014): Effect of childhood maltreatment on brain structure in adult patients with major depressive disorder and healthy participants. *J Psychiatry Neurosci* 39:50–59.
65. Teicher MH, Anderson CM, Polcari A (2012): Childhood maltreatment is associated with reduced volume in the hippocampal subfields CA3, dentate gyrus, and subiculum. *Proc Natl Acad Sci U S A* 109:E563–E572.
66. Heim C, Newport DJ, Heit S, Graham YP, Wilcox M, Bonsall R, *et al.* (2000): Pituitary-adrenal and autonomic responses to stress in women after sexual and physical abuse in childhood. *JAMA* 284:592–597.
67. Gouin JP, Glaser R, Malarkey WB, Beversdorf D, Kiecolt-Glaser JK (2012): Childhood abuse and inflammatory responses to daily stressors. *Ann Behav Med* 44:287–292.
68. Moylan S, Maes M, Wray NR, Berk M (2013): The neuroprogressive nature of major depressive disorder: Pathways to disease evolution and resistance, and therapeutic implications. *Mol Psychiatry* 18:595–606.
69. Saaltink DJ, Vreugdenhil E (2014): Stress, glucocorticoid receptors, and adult neurogenesis: A balance between excitation and inhibition? *Cell Mol Life Sci* 71:2499–2515.
70. Willner P, Scheel-Krüger J, Belzung C (2013): The neurobiology of depression and antidepressant action. *Neurosci Biobehav Rev* 37:2331–2371.
71. Stetler C, Miller GE (2011): Depression and hypothalamic-pituitary-adrenal activation: A quantitative summary of four decades of research. *Psychosom Med* 73:114–126.
72. Bockting CLH, Lok A, Visser I, Assies J, Koeter MW, Schene AH (2012): Lower cortisol levels predict recurrence in remitted patients with recurrent depression: A 5.5 year prospective study. *Psychiatry Res* 200:281–287.
73. Lok A, Mocking RJT, Ruhé HG, Visser I, Koeter MWJ, Assies J, *et al.* (2012): Longitudinal hypothalamic-pituitary-adrenal axis trait and state effects in recurrent depression. *Psychoneuroendocrinology* 37:892–902.
74. Vreeburg SA, Hoogendijk WJG, DeRijk RH, van Dyck R, Smit JH, Zitman FG, *et al.* (2013): Salivary cortisol levels and the 2-year course of depressive and anxiety disorders. *Psychoneuroendocrinology* 38:1494–1502.
75. Zorn JV, Schür RR, Boks MP, Kahn RS, Joëls M, Vinkers CH (2017): Cortisol stress reactivity across psychiatric disorders: A systematic review and meta-analysis. *Psychoneuroendocrinology* 77:25–36.
76. Morris MC, Rao U (2014): Cortisol response to psychosocial stress during a depressive episode and remission. *Stress* 17:51–58.
77. Raison CL, Miller AH (2003): When not enough is too much: The role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. *Am J Psychiatry* 160:1554–1565.
78. McKay MS, Zakzanis KK (2010): The impact of treatment on HPA axis activity in unipolar major depression. *J Psychiatr Res* 44:183–192.
79. Travis SG, Coupland NJ, Hegadoren K, Silverstone PH, Huang Y, Carter R, *et al.* (2016): Effects of cortisol on hippocampal subfields volumes and memory performance in healthy control subjects and patients with major depressive disorder. *J Affect Disord* 201:34–41.
80. Jin RO, Mason S, Mellon SH, Epel ES, Reus VI, Mahan L, *et al.* (2016): Cortisol/DHEA ratio and hippocampal volume: A pilot study in major depression and healthy controls. *Psychoneuroendocrinology* 72:139–146.
81. Maninger N, Wolkowitz OM, Reus VI, Epel ES, Mellon SH (2009): Neurobiological and neuropsychiatric effects of dehydroepiandrosterone (DHEA) and DHEA sulfate (DHEAS). *Front Neuroendocrinol* 30:65–91.
82. Kaymak SU, Demir B, Şentürk S, Tatar I, Aldur MM, Uluğ B (2010): Hippocampus, glucocorticoids and neurocognitive functions in patients with first-episode major depressive disorders. *Eur Arch Psychiatry Clin Neurosci* 260:217–223.
83. O’Brien JT, Lloyd A, McKeith I, Gholkar A, Ferrier N (2004): A longitudinal study of hippocampal volume, cortisol levels, and cognition in older depressed subjects. *Am J Psychiatry* 161:2081–2090.
84. Vythilingam M, Vermetten E, Anderson GM, Luckenbaugh D, Anderson ER, Snow J, *et al.* (2004): Hippocampal volume, memory, and cortisol status in major depressive disorder: Effects of treatment. *Biol Psychiatry* 56:101–112.
85. Colla M, Kronenberg G, Deuschle M, Meichel K, Hagen T, Bohrer M, *et al.* (2007): Hippocampal volume reduction and HPA-system activity in major depression. *J Psychiatr Res* 41:553–560.
86. Gerritsen L, Comijs HC, van der Graaf Y, Kooops AJG, Penninx BWJH, Geerlings MI (2011): Depression, hypothalamic-pituitary-adrenal axis, and hippocampal and entorhinal cortex volumes—the SMART Medea study. *Biol Psychiatry* 70:373–380.
87. Schuhmacher A, Mössner R, Jessen F, Scheef L, Block W, Belloche AC, *et al.* (2012): Association of amygdala volumes with cortisol secretion in unipolar depressed patients. *Psychiatry Res* 202:96–103.

88. Slavich GM, Irwin MR (2014): From stress to inflammation and major depressive disorder: A social signal transduction theory of depression. *Psychol Bull* 140:774–815.
89. Iwata M, Ota KT, Li XY, Sakaue F, Li N, Dutheil S, *et al.* (2016): Psychological stress activates the inflammasome via release of adenosine triphosphate and stimulation of the purinergic type 2X7 receptor. *Biol Psychiatry* 80:12–22.
90. Couch Y, Anthony DC, Dolgov O, Revischin A, Festoff B, Santos AI, *et al.* (2013): Microglial activation, increased TNF and SERT expression in the prefrontal cortex define stress-altered behaviour in mice susceptible to anhedonia. *Brain Behav Immun* 29:136–146.
91. Pan Y, Chen XY, Zhang QY, Kong LD (2014): Microglial NLRP3 inflammasome activation mediates IL-1 $\beta$ -related inflammation in prefrontal cortex of depressive rats. *Brain Behav Immun* 41:90–100.
92. Chesnokova V, Pechnick RN, Wawrowsky K (2016): Chronic peripheral inflammation, hippocampal neurogenesis, and behavior. *Brain Behav Immun* 58:1–8.
93. Setiawan E, Wilson AA, Mizrahi R, Rusjan PM, Miler L, Rajkowska G, *et al.* (2015): Role of translocator protein density, a marker of neuroinflammation, in the brain during major depressive episodes. *JAMA Psychiatry* 72:268–275.
94. Holmes SE, Hinz R, Conen S, Gregory CJ, Matthews JC, Anton-Rodriguez JM, *et al.* (2018): Elevated translocator protein in anterior cingulate in major depression and a role for inflammation in suicidal thinking: A positron emission tomography study. *Biol Psychiatry* 83:61–69.
95. Frodl T, Carballedo A, Hughes MM, Saleh K, Fagan A, Skokauskas N, *et al.* (2012): Reduced expression of glucocorticoid-inducible genes GILZ and SGK-1: High IL-6 levels are associated with reduced hippocampal volumes in major depressive disorder. *Transl Psychiatry* 2:1–8.
96. van Velzen LS, Schmaal L, Milaneschi Y, van Tol MJ, van der Wee NJA, Veltman DJ, *et al.* (2017): Immunometabolic dysregulation is associated with reduced cortical thickness of the anterior cingulate cortex. *Brain Behav Immun* 60:361–368.
97. Savitz J, Frank MB, Victor T, Bebak M, Bellgowan PS, McKinney BA, *et al.* (2013): Inflammation and neurological disease-related genes are differentially expressed in depressed patients with mood disorders and correlate with morphometric and functional imaging abnormalities. *Brain Behav Immun* 31:161–171.
98. Sowa-Kućma M, Styczeń K, Siwek M, Misztak P, Nowak RJ, Dudek D, *et al.* (2018): Are there differences in lipid peroxidation and immune biomarkers between major depression and bipolar disorder: Effects of melancholia, atypical depression, severity of illness, episode number, suicidal ideation and prior suicide attempts. *Prog Neuropsychopharmacol Biol Psychiatry* 81:372–383.
99. Dunjic-Kostic B, Ivkovic M, Radonjic NV, Petronijevic ND, Pantovic M, Damjanovic A, *et al.* (2013): Melancholic and atypical major depression—Connection between cytokines, psychopathology and treatment. *Prog Neuropsychopharmacol Biol Psychiatry* 43:1–6.
100. Eller T, Vasar V, Shlik J, Maron E (2008): Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. *Prog Neuropsychopharmacol Biol Psychiatry* 32:445–450.
101. Lindqvist D, Dhabhar FS, James SJ, Hough CM, Jain FA, Bersani FS, *et al.* (2017): Oxidative stress, inflammation and treatment response in major depression. *Psychoneuroendocrinology* 76:197–205.
102. Filipović D, Todorović N, Bernardi RE, Gass P (2017): Oxidative and nitrosative stress pathways in the brain of socially isolated adult male rats demonstrating depressive- and anxiety-like symptoms. *Brain Struct Funct* 222:1–20.
103. Che Y, Wang JF, Shao L, Young LT (2010): Oxidative damage to RNA but not DNA in the hippocampus of patients with major mental illness. *J Psychiatry Neurosci* 5:296–302.
104. Meyer JH, Wilson AA, Sagrati S, Miler L, Rusjan P, Bloomfield PM, *et al.* (2009): Brain monoamine oxidase A binding in major depressive disorder. *Arch Gen Psychiatry* 66:1304–1312.
105. Michel TM, Frangou S, Thiemeyer D, Camara S, Jecel J, Nara K, *et al.* (2007): Evidence for oxidative stress in the frontal cortex in patients with recurrent depressive disorder—A postmortem study. *Psychiatry Res* 151:145–150.
106. Gawryluk JW, Wang JF, Andreazza AC, Shao L, Young LT (2011): Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. *Int J Neuropsychopharmacol* 14:123–130.
107. Lindqvist D, Mueller S, Mellon SH, Su Y, Epel ES, Reus VI, *et al.* (2014): Peripheral antioxidant markers are associated with total hippocampal and CA3/dentate gyrus volume in MDD and healthy controls—Preliminary findings. *Psychiatry Res* 224:168–174.
108. Baek S-E, Lee G-J, Rhee C-K, Rho D-Y, Kim D-H, Huh S, *et al.* (2016): Decreased total antioxidant activity in major depressive disorder patients non-responsive to antidepressant treatment. *Psychiatry Investig* 13:222–226.
109. Śliwiński T (2015): Elevated level of DNA damage and impaired repair of oxidative DNA damage in patients with recurrent depressive disorder. *Med Sci Monit* 21:412–418.
110. Czarny P, Kwiatkowski D, Toma M, Kubiak J, Silwinska A, Talarowska M, *et al.* (2017): Impact of single nucleotide polymorphisms of base excision repair genes on DNA damage and efficiency of DNA repair in recurrent depression disorder. *Mol Neurobiol* 54:4150–4159.
111. Jorgensen A, Krogh J, Miskowiak K, Bolwig TG, Kessing LV, Fink-Jensen A, *et al.* (2013): Systemic oxidatively generated DNA/RNA damage in clinical depression: Associations to symptom severity and response to electroconvulsive therapy. *J Affect Disord* 149:355–362.
112. Stefanescu C, Ciobica A (2012): The relevance of oxidative stress status in first episode and recurrent depression. *J Affect Disord* 143:34–38.
113. Talarowska M, Orzechowska A, Szemraj J, Su K-P, Maes M, Galecki P (2014): Manganese superoxide dismutase gene expression and cognitive functions in recurrent depressive disorder. *Neuropsychobiology* 70:23–28.
114. Bekris S, Antoniou K, Daskas S, Papadopoulou-Daifoti Z (2005): Behavioural and neurochemical effects induced by chronic mild stress applied to two different rat strains. *Behav Brain Res* 161:45–59.
115. Luo DD, An SC, Zhang X (2008): Involvement of hippocampal serotonin and neuropeptide Y in depression induced by chronic unpredictable mild stress. *Brain Res Bull* 77:8–12.
116. Harro J, Tönissaa M, Eller M, Kask A, Oreland L (2001): Chronic variable stress and partial 5-HT denervation by parachloroamphetamine treatment in the rat: Effects on behavior and monoamine neurochemistry. *Brain Res* 899:227–239.
117. López-Figueroa AL, Norton CS, López-Figueroa MO, Armellini-Dodel D, Burke S, Akil H, *et al.* (2004): Serotonin 5-HT<sub>1A</sub>, 5-HT<sub>1B</sub>, and 5-HT<sub>2A</sub> receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. *Biol Psychiatry* 55:225–233.
118. Gryglewski G, Lanzenberger R, Kranz GS, Cumming P (2014): Meta-analysis of molecular imaging of serotonin transporters in major depression. *J Cereb Blood Flow Metab* 34:1096–1103.
119. Kambeitz JP, Howes OD (2015): The serotonin transporter in depression: Meta-analysis of in vivo and post mortem findings and implications for understanding and treating depression. *J Affect Disord* 186:358–366.
120. Maes M, Ringel K, Kubera M, Berk M, Rybakowski J (2012): Increased autoimmune activity against 5-HT: A key component of depression that is associated with inflammation and activation of cell-mediated immunity, and with severity and staging of depression. *J Affect Disord* 136:386–392.
121. Grimm S, Luborzewski A, Schubert F, Merkyl A, Kronenberg G, Colla M, *et al.* (2012): Region-specific glutamate changes in patients with unipolar depression. *J Psychiatr Res* 46:1059–1065.
122. Sun H, Su R, Zhang X, Wen J, Yao D, Gao X, *et al.* (2017): Hippocampal GR- and CB1-mediated mGluR5 differentially produces susceptibility and resilience to acute and chronic mild stress in rats. *Neuroscience* 357:295–302.

123. De Vasconcellos-Bittencourt APS, Vendite DA, Nassif M, Crema LM, Frozza R, Thomazi AP, *et al.* (2011): Chronic stress and lithium treatments alter hippocampal glutamate uptake and release in the rat and potentiate necrotic cellular death after oxygen and glucose deprivation. *Neurochem Res* 36:793–800.
124. Jett JD, Bulin SE, Hatherall LC, McCartney CM, Morilak DA (2017): Deficits in cognitive flexibility induced by chronic unpredictable stress are associated with impaired glutamate neurotransmission in the rat medial prefrontal cortex. *Neuroscience* 346:284–297.
125. Yuen EY, Wei J, Liu W, Zhong P, Li X, Yan Z (2012): Repeated stress causes cognitive impairment by suppressing glutamate receptor expression and function in prefrontal cortex. *Neuron* 73:962–977.
126. John CS, Smith KL, Van't Veer A, Gompf HS, Carlezon WA, Cohen BM, *et al.* (2012): Blockade of astrocytic glutamate uptake in the prefrontal cortex induces anhedonia. *Neuropsychopharmacology* 37:2467–2475.
127. de Diego-Adelino J, Portella MJ, Gómez-Ansón B, Lopez-Moruelo O, Serra-Blasco M, Yolanda V, *et al.* (2013): Hippocampal abnormalities of glutamate/glutamine, *N*-acetylaspartate and choline in patients with depression are related to past illness burden. *J Psychiatry Neurosci* 38:107–116.
128. Portella MJ, de Diego-Adelino J, Gómez-Ansón B, Morgan-Ferrando R, Vives Y, Puigdemont D, *et al.* (2011): Ventromedial prefrontal spectroscopic abnormalities over the course of depression: A comparison among first episode, remitted recurrent and chronic patients. *J Psychiatr Res* 45:427–434.
129. Croarkin PE, Nakonezny PA, Husain MM, Melton T, Buyukdura JS, Kennard BD, *et al.* (2013): Evidence for increased glutamatergic cortical facilitation in children and adolescents with major depressive disorder. *JAMA Psychiatry* 70:291–299.
130. Cavus I, Pan JW, Hetherington HP, Walid A-S, Hitten PS, Vives KP, *et al.* (2008): Decreased hippocampal volume on MRI is associated with increased extracellular glutamate in epilepsy patients. *Epilepsia* 49:1358–1366.
131. Lee Y, Son H, Kim G, Kim S, Lee DH, Roh GS, *et al.* (2013): Glutamate deficiency in the prefrontal cortex increases depressive-like behaviors in male mice. *J Psychiatry Neurosci* 38:183–191.
132. Chowdry GM, Zhang J, Thomas M, Banas M, Ma X, Pittman B, *et al.* (2017): Transiently increased glutamate cycling in rat PFC is associated with rapid onset of antidepressant effects. *Mol Psychiatry* 22:120–126.
133. Sancora G, Banas M (2013): From pathophysiology to novel antidepressant drugs: Glial contributions to the pathology and treatment of mood disorders. *Biol Psychiatry* 73:1172–1179.
134. Luscher B, Shen Q, Sahir N (2011): The GABAergic deficit hypothesis of major depressive disorder. *Mol Psychiatry* 16:383–406.
135. Hemanth Kumar BS, Mishra SK, Rana P, Singh S, Khushu S (2012): Neurodegenerative evidences during early onset of depression in CMS rats as detected by proton magnetic resonance spectroscopy at 7T. *Behav Brain Res* 232:53–59.
136. Ma K, Xu A, Cui S, Sun MR, Xue YC, Wang JH (2016): Impaired GABA synthesis, uptake and release are associated with depression-like behaviors induced by chronic mild stress. *Transl Psychiatry* 6:e910.
137. Feng J, Cai X, Zhao J, Yan Z (2001): Serotonin receptors modulate GABA<sub>A</sub> receptor channels through activation of anchored protein kinase C in prefrontal cortical neurons. *J Neurosci* 21:6502–6511.
138. Rubio-Casillas A, Fernández-Guasti A (2016): The dose makes the poison: From glutamate-mediated neurogenesis to neuronal atrophy and depression. *Rev Neurosci* 27:599–622.
139. Abdallah CG, Jackowski A, Sato JR, Mao X, Kang G, Cheema R, *et al.* (2015): Prefrontal cortical GABA abnormalities are associated with reduced hippocampal volume in major depressive disorder. *Eur Neuropsychopharmacol* 25:1082–1090.
140. Gabbay V, Mao X, Klein RG, Ely BA, Babb JS, Panzer AM, *et al.* (2012): Anterior cingulate cortex  $\gamma$ -aminobutyric acid in depressed adolescents: Relationship to anhedonia. *Arch Gen Psychiatry* 69:139–149.
141. Hasler G, van der Veen JW, Tumonis T, Meyers N, Shen J, Drevets WC (2007): Reduced prefrontal glutamate/glutamine and  $\gamma$ -aminobutyric acid levels in major depression determined using proton magnetic resonance spectroscopy. *Arch Gen Psychiatry* 64:193–200.
142. Levinson AJ, Fitzgerald PB, Favalli G, Blumberger DM, Daigle M, Daskalakis ZJ (2010): Evidence of cortical inhibitory deficits in major depressive disorder. *Biol Psychiatry* 67:458–464.
143. Price RB, Shungu DC, Mao X, Nestadt P, Kelly C, Collins KA, *et al.* (2009): Amino acid neurotransmitters assessed by proton magnetic resonance spectroscopy: Relationship to treatment resistance in major depressive disorder. *Biol Psychiatry* 65:792–800.
144. Capuron L, Miller AH (2011): Immune system to brain signaling: Neuropsychopharmacological implications. *Pharmacol Ther* 130:226–238.
145. Lugo-Huitron R, Muniz PU, Pineda P, Pedrazza-Chaverri J, Rios C, Perex-de la Cruz V (2013): Quinolinic acid: An endogenous neurotoxin with multiple targets. *Oxid Med Cell Longev* 2013:104024.
146. Savitz J, Drevets WC, Smith CM, Victor TA, Wurfel BE, Bellgowen PSF, *et al.* (2015): Putative neuroprotective and neurotoxic kynurenine pathway metabolites are associated with hippocampal and amygdalar volumes in subjects with major depressive disorder. *Neuropsychopharmacology* 40:463–471.
147. Meier TB, Drevets WC, Wurfel BE, Ford BN, Morris HM, Victor TA, *et al.* (2016): Relationship between neurotoxic kynurenine metabolites and reductions in right medial prefrontal cortical thickness in major depressive disorder. *Brain Behav Immun* 53:39–48.
148. Parrott JM, Redus L, Santana-Coelho D, Morales J, Gao X, O'Connor JC (2016): Neurotoxic kynurenine metabolism is increased in the dorsal hippocampus and drives distinct depressive behaviors during inflammation. *Transl Psychiatry* 6:e918.